NVOS — Novo Integrated Sciences Income Statement
0.000.00%
Last trade - 00:00
- $12.67m
- $15.01m
- $12.57m
- 30
- 69
- 14
- 31
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.42 | 7.86 | 9.31 | 11.7 | 12.6 |
Cost of Revenue | |||||
Gross Profit | 3.52 | 3.06 | 3.82 | 4.8 | 4.95 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 9.83 | 12.5 | 13.7 | 36.8 | 21.1 |
Operating Profit | -0.408 | -4.61 | -4.35 | -25 | -8.55 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.404 | -4.92 | -4.47 | -33.1 | -13.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.404 | -4.92 | -4.47 | -33 | -13.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.392 | -4.92 | -4.46 | -32.8 | -13.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.392 | -4.92 | -4.46 | -32.8 | -13.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.241 | -1.97 | -2.06 | -7.83 | -1.3 |